Specific treatments are currently not available for triple negative breast cancer (TNBC), a type of tumor that lacks the receptors targeted by many breast cancer therapies.
Although many TNBC tumors lack two tumor suppressors, RB1 and p53, the specific downstream pathways that can be targeted as potential treatments for these tumors have not been identified.
In this issue of the JCI, a team led by Eldad Zacksenhaus at Toronto General Research Institute discovered that the growth of TNBC-like breast tumors is supported by enhanced mitochondrial function.
They then identified an FDA-approved drug, tigecycline, that blocks this upregulation and reduces the growth of TNBC-like tumors in mice.
This work suggests that inhibiting mitochondrial protein translation could potentially be a successful treatment for TNBC.